© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#ICAAC 2006

Click Here for More Conferences
Click Here for ICAAC Online
HIV: The Basics
The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Diary of a Doc: Vaccine Update at ICAAC

Developing a vaccine to prevent HIV infection has been a significant challenge.

ICAAC: Trizivir vs. Reyataz/Combivir

A new study suggests that 48 weeks of treatment with Trizivir® is comparable to a protease inhibitor-based regimen.

ICAAC: Norvir-Boosted Lexiva vs. Reyataz

Early data from a study comparing Lexiva (fosamprenavir) to Reyataz (atazanavir), both combined with low-dose Norvir (ritonavir), suggest that...

Predictive Value of Viral Load Testing Questioned

While the value of viral load testing is pretty much undisputed with respect to monitoring HIV-positive people while on treatment, a recent st...

ICAAC: Prezista and Aptivus on Drug-Resistant HIV

Three reports presented Friday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco have shed...

ICAAC: MK-0518 Potent for Treatment Experienced

New follow-up data from a clinical trial evaluating Merck’s experimental integrase inhibitor MK-0518 in HIV-positive people who have tried and...

ICAAC: More Drug-Resistant HIV?

A growing number of HIV-positive people who have never taken HIV medications appear to have virus mutations that can cause drug resistance to...

ICAAC Opens in San Francisco

The 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) opened yesterday in San Francisco with HIV and drug r...

Predicting Responses to Aptivus or Prezista

Two companies offering phenotypic drug resistance testing provided new data.

Prezista Women’s Study Opens for Enrollment

Tibotec Therapeutics has announced the initiation of a clinical trial evaluating different responses to HIV treatment among women and men. The...

Abortion Pill for HIV? Questions Still Remain

One of the most intriguing compounds to be studied as an HIV therapy is mifepristone, a controversial medication sold in the United States as...

MK-0518 Appears Lipid Friendly

New data suggest that MK-0518 does not cause increased cholesterol or triglyceride as a side effect of treatment. The “late breaker” report, h...
Advertisement
Newsfeed
Treatment News
Features
Opinions